CN102786462B - Arbidol hydrochloride crystal B-type and preparation method are applied with in medicine and health product - Google Patents
Arbidol hydrochloride crystal B-type and preparation method are applied with in medicine and health product Download PDFInfo
- Publication number
- CN102786462B CN102786462B CN201110128507.1A CN201110128507A CN102786462B CN 102786462 B CN102786462 B CN 102786462B CN 201110128507 A CN201110128507 A CN 201110128507A CN 102786462 B CN102786462 B CN 102786462B
- Authority
- CN
- China
- Prior art keywords
- type
- arbidol hydrochloride
- hydrochloride monohydrate
- monohydrate crystal
- arbidol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of crystal B-type state of matter of the Arbidol hydrochloride monohydrate shown in formula (I)；The preparation method of Arbidol hydrochloride monohydrate crystal B-type sample；The product prepared as active component using Arbidol hydrochloride monohydrate crystal B-type material, described product includes medicine and health product, and the application in Arbidol hydrochloride monohydrate crystal B-type disease preventing and treating and health care.
Description
Technical field
The present invention relates to Arbidol hydrochloride monohydrate one crystal B-type state of matter, Arbidol hydrochloride one water
The preparation method of compound crystal B-type sample, uses Arbidol hydrochloride monohydrate crystal B-type material as the product of active component
Product, and the purposes of Arbidol hydrochloride monohydrate crystal B-type, belong to pharmaceutical technology field.
Background technology
Arbidol hydrochloride, English entitled Arbidol hydrochloride, shown in molecular structure such as formula (I)
Abiduoer is to be developed by former Soviet Union's pharmaceutical chemistry research center, within 1993, lists in Russia, is used for preventing and treating A, B
The influenza that type influenza virus causes and other acute respiratory virus infections, and the complication of influenza virus can be stoped
Occur, have no side effect, belong to the antiviral drugs of wide spectrum, for interferon inducer and immunostimulant[1-3]。
Abiduoer medicine effect be by activate 2,5-oligo-adenylate synthetase and specificity suppression virus envelope with
The fusion of host's fine film blocks the duplication of influenza virus[4]。
Find that existing patent majority is to Abiduoer different dosage form or compound recipe and the guarantor of purposes by Chinese patent retrieval
Protect:
Zhongqi Pharmaceutical Technology's invention has been recorded in Chinese patent CN 1589790A (publication number)
" Abedol slow release tablet and preparation method thereof "[5].It is directed to invent the slow releasing tablet of a kind of antiviral drugs, by profit
It is prepared into hydrogel matrix slow releasing tablet and waxiness matrix sustained release tablet by the water-fast characteristic of Abiduoer, invents simultaneously
The preparation method of these two kinds of slow releasing preparation.
Baili Pharmaceutical Co., Ltd., Sichuan Prov.'s invention has been recorded in Chinese patent CN 1868470A (publication number)
" Abiduoer granular formulation "[6].It relates to having invented a kind of Abiduoer granular formulation.
Chinese patent CN 101904826A (publication number) has been recorded Li Weidong invention " arbidol HCl mouth collapses
Solve sheet and preparation method thereof "[7].It relates to having invented arbidol HCl a kind of and absorbs fast and that bioavailability is high mouth and collapse
Solve sheet and preparation method thereof.
SHANDONG LUOXIN PHARMACY STOCK Co., LTD.'s invention has been recorded in Chinese patent CN 101653425A (publication number)
" a kind of arbidol hydrochloride medicament composition dispersible tablets and preparation method thereof "[8].It relates to having invented a kind of substrate's appearance, hard
Degree and dispersing uniformity all preferably arbidol HCl compositions dispersible tablet and preparation method thereof.
" Abiduoer and the salt thereof of Shi Xiulan, Xu Hua invention has been recorded in Chinese patent CN 1792362A (publication number)
Intravenous administration formulation and preparation method "[9].Its side relating to having invented the intravenous administration formulation preparing Abiduoer or its salt
Method, and the application that this intravenous administration formulation is in terms of resisiting influenza virus.
Zhongqi Pharmaceutical Technology's invention has been recorded in Chinese patent CN 1535680A (publication number)
" Abidor inclusion compound "[10].It relates to having invented a kind of new Abiduoer and cyclodextrin or the molecule of its derivant
Clathrate, and the preparation method of this clathrate and they application in pharmaceutical preparation.
Zhongqi Pharmaceutical Technology's invention has been recorded in Chinese patent CN 1572298A (publication number)
" containing the compound preparation of Abiduoer "[11].Its compound preparation relating to having invented a kind of Abiduoer, this compound preparation medicine
Thing is applicable to the respiratory infection diseases caused because of virus.
Chinese patent CN 1839829A (publication number) has been recorded history show orchid invention " containing Abiduoer and cattle sulphur
The antiviral cold compound formulation of acid "[12].It is multiple that it relates to having invented a kind of antiviral cold containing Abiduoer and taurine
Square preparation and application thereof.
" a kind of compound recipe Abiduoer wide spectrum of Li Xin invention has been recorded in Chinese patent CN 1546019A (publication number)
Antiviral cold medicine "[13].It relates to having invented a kind of main by Abiduoer, acetaminophen and chlorphenamine or chlorine thunder
The compound recipe Abiduoer broad-spectrum antiviral cold medicine of his fixed composition.
Zhongqi Pharmaceutical Technology's invention has been recorded in Chinese patent CN 1552321A (publication number)
" Abiduoer preparation prevention and treatment SARS virus medicine in purposes "[14].Its by In vitro cell experiment prove Ah
Than Duo Er, SARS virus is had significant inhibitory action and as preventing and the medicinal application of SARS virus can be treated in facing
Bed.
In Chinese patent CN 101011389A (publication number), in record Liao Shi medicine group, strange pharmaceutical technology (Shijiazhuang) has
" Abiduoer purposes in preparation prevention and treatment hepatitis B medicament " of limit company invention[15].It passes through experiment in vitro
Prove that Abiduoer has significant inhibitory action and can answer as the medicine of prevention and treatment hepatitis B hepatitis B
For clinic.
Zhongqi Pharmaceutical Technology's invention has been recorded in Chinese patent CN 1596892A (publication number)
" Abiduoer preparation prevention and treatment hepatitis B, inhibition of HIV medicine in purposes "[16].It is demonstrate,proved by experiment in vitro
Bright Abiduoer hepatitis B, inhibition of HIV are had significant inhibitory action and can as prevention and treatment hepatitis B,
The medicinal application of inhibition of HIV is in clinic.
" a kind of anti-hantavirus of Wuhan University's invention has been recorded in Chinese patent CN 101461805A (publication number)
The purposes of medicament arbidol "[17].Its a kind of new application relating to having invented Abiduoer anti-hantavirus.
It is published in Journal of Chinese Hospital Pharmacy 2006 the 4th phase of volume 26 page 397 about " salt by literature search to one
The acid preparation of Abiduoer microemulsion and quality evaluation thereof " article[18], describe employing microemulsion oral as pharmaceutical carrier preparation
The method of Abiduoer microemulsion has also carried out quality evaluation to it.By different auxiliary material and the different ratio of organic solvent, dripping
On the basis of the method for determining prepares pseudo-ternary phase diagram, according to phasor optimizing prescriptions, investigate the Stability and morphology of microemulsion formulation respectively
Particle diameter, the content of Abiduoer in microemulsion with high effective liquid chromatography for measuring.Result display Abiduoer microemulsion is stable, transmission
Under Electronic Speculum rounded, be evenly distributed and be distributed in Gauss, and the Abiduoer content of high effective liquid chromatography for measuring is high, side
Method is reliable, reproducible.
The crystal formation report closing Arbidol hydrochloride is found no through searching document and domestic and international patent.
There is essential difference with existing patent or document in the present invention, its access point is from Arbidol hydrochloride monohydrate
The research of crystal-form substances existence is started with, and by screening polymorph technical research, seeks in the raw material aspect of active constituents of medicine
Look for, find novel crystal forms kind and the state feature of Arbidol hydrochloride solid matter, and by crystal formation research and clinical and health care
Application combine, for finds, find, develop have optimal efficacy Arbidol hydrochloride state offer basic scientific research number
According to；Meanwhile, also for apply for that national or international intellectual property is sent out on the basis of Arbidol hydrochloride crystalline solid form raw material
Bright patent protection provides scientific basis.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of new of the Arbidol hydrochloride monohydrate shown in formula (I)
Crystal formation, i.e. crystal B-type
Another technical problem that the invention solves the problems that is to provide the system of Arbidol hydrochloride monohydrate crystal B-type material
Preparation Method.
Another technical problem that the invention solves the problems that is to provide Arbidol hydrochloride monohydrate crystal B-type composition conduct
The product of active component.
Another technical problem that the invention solves the problems that is to provide the application of Arbidol hydrochloride monohydrate crystal B-type.
Specifically, for solving the technical problem that, adopt the following technical scheme that:
1. Arbidol hydrochloride monohydrate crystal B-type sample morphology feature:
1.1 Arbidol hydrochloride monohydrate crystal B-type states of matter, (the CuK when using powder x-ray diffraction analysisα
Radiation), show as Height%=100 peak position in 2-Theta=4.8 ± 0.2 ° or Place also there are
30 its positions of diffraction maximum respectively in 2-Theta (°) ± 0.2 ° value orValue has and is expressed as:
And diffraction maximum relative intensity value allows Height% ± 10% excursion (Fig. 1).
1.2 Arbidol hydrochloride monohydrate crystal B-type states of matter, its infrared absorption spectroscopy (Fig. 2) 3503,
3322、3120、3058、2970、2897、2844、2590、1778、1675、1581、1503、1474、1463、1439、1424、
1413、1383、1363、1324、1286、1256、1231、1197、1183、1162、1150、1130、1088、1054、1042、
1024、1000、956、943、926、892、861、840、793、781、740、726、700、688、653cm-1±2cm-1Absorption
The infrared spectrum characteristic peak positions that peak is presented by Arbidol hydrochloride monohydrate crystal B-type solid matter.
1.3 Arbidol hydrochloride monohydrate crystal B-type states of matter, in its DSC collection of illustrative plates, (Fig. 3) when heating rate is
There are two Peak endothermic peaks when 10 DEG C per minute, transformation value is respectively at 134 DEG C ± 3 DEG C and 180 DEG C ± 3 DEG C.
1.4 Arbidol hydrochloride monohydrate crystal B-type states of matter, its melting point values is 141 DEG C ± 2 DEG C.
2. the preparation method characteristic of Arbidol hydrochloride monohydrate crystal B-type sample:
2.1 preparation methoies that the invention provides a kind of Arbidol hydrochloride monohydrate crystal B-type sample, is characterized in that
Use single methanol, acetone, acetonitrile, isopropanol, ethanol, normal propyl alcohol, n-butyl alcohol, ethyl acetate, oxolane, dioxane,
Dichloromethane, DMF, DMSO, chloroform, pyridine solvent under 10 DEG C～80 DEG C of temperature conditionss by complete for Arbidol hydrochloride sample
A certain amount of water is entered and through ambient temperature 10 DEG C～80 DEG C, ambient humidity 10%～75%, normal pressure or vacuum pressure in adding after dissolving
Condition prepares Arbidol hydrochloride monohydrate crystal B-type sample.
2.2 preparation methoies that the invention provides alternative Arbidol hydrochloride monohydrate crystal B-type sample, it is special
Levy be use methanol, acetone, acetonitrile, isopropanol, ethanol, normal propyl alcohol, n-butyl alcohol, ethyl acetate, oxolane, dioxane,
Arbitrarily two or more presses different ratio mixed solvent system at 10 DEG C～80 for dichloromethane, DMF, DMSO, chloroform, pyridine
A certain amount of water is entered and through ambient temperature 10 DEG C～80 in adding after being completely dissolved by Arbidol hydrochloride sample under DEG C temperature conditions
DEG C, ambient humidity 10%～75%, normal pressure or vacuum pressure condition prepare Arbidol hydrochloride monohydrate crystal B-type sample
Product.
3. Arbidol hydrochloride monohydrate crystal B-type is as using dosage and the purposes feature of active substance:
3.1 present invention also provide for a kind of product, become using Arbidol hydrochloride monohydrate crystal B-type composition as activity
Divide and contain other adjuvants.Product of the present invention, including medicine, health product.
In described product, the crystal form purity of Arbidol hydrochloride monohydrate crystal B-type is 1%～100%.
The dosage form of described product is selected from tablet, capsule, pill, injection, slow release or controlled release agent, powder.
3.2 the invention provides Arbidol hydrochloride monohydrate crystal B-type material as active component develop various
Product, including medicine, health product, it is characterized in that using Arbidol hydrochloride monohydrate crystal B-type material as active component,
Its every daily ingestion dosage is in 5mg～50g scope.
3.3 the invention provides Arbidol hydrochloride monohydrate crystal B-type material as active component develop various
Product, including medicine, health product, it is characterized in that employing containing Arbidol hydrochloride monohydrate crystal B-type material conduct
Active component ensure that its Absorption Characteristics in vivo, effective bioavailability, effective blood drug concentration, when stablizing lasting
Between and reach prevention, treatment, health-care effect and the application made the most of the advantage.
4. the Absorption Characteristics after Arbidol hydrochloride monohydrate crystal B-type sample is oral:
The invention provides the product that Arbidol hydrochloride monohydrate crystal B-type material is developed as active component, bag
Include medicine and health product, the biological absorption effect after oral administration, it is characterized in that Arbidol hydrochloride monohydrate crystal B-type thing
Matter as active component by quickly play in blood after gastrointestinal tract 2 minutes prevention, treatment, health-care effect and have 12 hours with
The upper mounting plate advantage function cycle.Accompanying drawing 4 is given after Arbidol hydrochloride monohydrate crystal B-type sample oral administration absorbs rat
Internal plasma concentration curve.
5. the pharmaceutical applications of Arbidol hydrochloride monohydrate crystal B-type.
The invention provides the application in preparation treatment antiviral drugs of the Arbidol hydrochloride monohydrate crystal B-type.
Preferably virus is selected from A, Type B influenza virus, SARS virus, hepatitis B, inhibition of HIV, anti-hantavirus.
Accompanying drawing explanation
The x-ray diffractogram of powder spectrum of Fig. 1 Arbidol hydrochloride monohydrate crystal B-type sample
The infrared absorpting light spectra of Fig. 2 Arbidol hydrochloride monohydrate crystal B-type sample
The DSC collection of illustrative plates of Fig. 3 Arbidol hydrochloride monohydrate crystal B-type sample
After the absorption of Fig. 4 Arbidol hydrochloride monohydrate crystal B-type sample oral administration, the blood drug level in rat body is bent
Line
Detailed description of the invention
For more preferably illustrating that technical scheme, spy provide following example, but the present invention is not limited to this.
Embodiment 1
The preparation method of Arbidol hydrochloride monohydrate crystal B-type sample:
The preparation method of Arbidol hydrochloride monohydrate crystal B-type sample, is characterized in that using 1L methanol solvate 65
The water of same volume is entered temperature 65 DEG C in slowly adding after being completely dissolved by 20g Arbidol hydrochloride sample under DEG C counterflow condition
Under the conditions of reflux after 3 hours filtered while hot put crystallize by gentle and quiet for filtrate chamber, Arbidol hydrochloride monohydrate can be obtained
Crystal form samples.
The x-ray diffractogram of powder of gained Arbidol hydrochloride monohydrate crystal form sample is composed as shown in Figure 1
The infrared absorpting light spectra of gained Arbidol hydrochloride monohydrate crystal form sample is as shown in Figure 2
The DSC collection of illustrative plates of gained Arbidol hydrochloride monohydrate crystal form sample is as shown in Figure 3
Above spectrum data result shows, the crystal formation of the present embodiment gained crystal is that Arbidol hydrochloride monohydrate is brilliant
Type B.
Embodiment 2
The preparation method of Arbidol hydrochloride monohydrate crystal B-type sample:
The preparation method of Arbidol hydrochloride monohydrate crystal B-type sample, is characterized in that adding volume ratio is 1: 1 each 1L
Methanol and water mixed solvent 20g Arbidol hydrochloride sample is refluxed 3 hours under 65 DEG C of temperature conditionss after filtered while hot also
Crystallize is put by gentle and quiet for filtrate chamber, Arbidol hydrochloride monohydrate crystal form sample can be obtained.
The x-ray diffractogram of powder of gained Arbidol hydrochloride monohydrate crystal form sample is composed as shown in Figure 1
The infrared absorpting light spectra of gained Arbidol hydrochloride monohydrate crystal form sample is as shown in Figure 2
The DSC collection of illustrative plates of gained Arbidol hydrochloride monohydrate crystal form sample is as shown in Figure 3
Above spectrum data result shows, the crystal formation of the present embodiment gained crystal is that Arbidol hydrochloride monohydrate is brilliant
Type B.
The problem needing explanation: due to for preparing the single organic of Arbidol hydrochloride monohydrate crystal B-type sample
Solvent has two kinds multiple, to may be used for preparing Arbidol hydrochloride monohydrate crystal B-type sample or above group of solvents
Conjunction has over one hundred kind, and every kind of organic solvent boiling point values is different, different to Arbidol hydrochloride dissolution properties, causes and is using difference
The ambient temperature of its experiment, humidity, time, pressure when preparing Arbidol hydrochloride monohydrate crystal B-type sample under solvent condition
The variate-values such as power all there is some difference property and constant interval scope.
Embodiment 3
Arbidol hydrochloride monohydrate crystal B-type sample is in rat body absorption feature and blood drug level feature:
Laboratory animal uses the SD male rat of body weight 210 ± 20g, and normal condition is raised, and freely drinks water, fasting 12 hours
After, utilize solid form delivery device (this laboratory patented product) to give Arbidol hydrochloride monohydrate crystal B-type medicine and (press
300mg/kg dosage), respectively at be administered after 0.03,0.08,0.25,0.5,1.0,2.0,3.0,4.0,6.0,8.0,10.0,
12.0,24.0,36.0 (h) time point extracting vein blood (ball rear vein beard takes blood) about 0.3mL, 5000rpm is centrifuged 10min；Take
150uL blood plasma, adds 1mL ethyl acetate, and vortex oscillation 3min, 13400rpm is centrifuged 10min, takes supernatant 900uL, N2After drying up
Adding 75uL flowing to redissolve mutually, vortex oscillation 3min, 13400rpm is centrifuged 5min, takes supernatant 70uL and carries out HPLC detection.HPLC examines
Survey condition: detecting system is Agilent 1200, chromatographic column is Agilent Eclipse TC-C18(2), 250 × 4.6mm,
5um, flowing is methanol mutually: 1% triethylamine aqueous solution (pH=3.0)=67: 33, and sample size is 30uL, and flow velocity is 1mL/min,
Column temperature is 35 DEG C, and detection wavelength is 315nm.Testing result see table.
Arbidol hydrochloride monohydrate crystal B-type sample plasma drug concentration data
Test result indicate that: Arbidol hydrochloride monohydrate crystal B-type chemical solids material can be by rat resorption, and it is special
Levying is can be absorbed after Arbidol hydrochloride monohydrate crystal B-type solid drugs oral administration, after the 2 minutes quickly at blood
Liquid plays prevention, treatment, health-care effect and has 12 hours with the upper mounting plate advantage function cycle.Arbidol hydrochloride one is hydrated
As active component, thing crystal B-type material ensure that its Absorption Characteristics in vivo, effective bioavailability, effective blood medicine are dense
Spend, stablize duration and reach prevention, treatment, health-care effect and the application made the most of the advantage.
Embodiment 4
Arbidol hydrochloride monohydrate crystal B-type material is as the drug products for administration dosage of active component:
Use the medicinal tablet that Arbidol hydrochloride monohydrate crystal B-type sample manufactures as active constituents of medicine
Or other preparations, it is characterized in that containing Arbidol hydrochloride monohydrate crystal B-type as the active component of medicine, be given daily
Dosage is 300mg, can be prepared as three times a day/each 1 100mg conventional tablet respectively, and every day, 2 times/each 1 150mg was common
Tablet or the tablet type of 1 time/each 1 300mg every day.
The problem needing explanation: the Arbidol hydrochloride monohydrate crystal B-type pharmaceutical composition that the present invention relates to is having
Multifactor impact perhaps is there are, such as: the purposes for preventing with treat is different and causes every day on the dosage of effect composition
The difference of dosage；Ill character is different from the ill order of severity and causes the different of dosage every day；Gender, year
Age, the difference of body surface area, route of administration, administration number of times, therapeutic purposes are different and cause the difference of dosage every day；This
Outward, the absorption existed between crystal form samples and blood drug level is not equal, also results in the present invention and is using Arbidol hydrochloride one water
Suitable dosage ranges every day of compound crystal B-type composition is 0.01～200mg/kg body weight, preferably 1～100mg/kg body weight.Make
Used time should formulate Arbidol hydrochloride monohydrate crystal B-type effective ingredient according to actual prevention with treatment different situations demand
Accumulated dose scheme, and multiple or single administering mode can be divided into complete.
Embodiment 5
Arbidol hydrochloride monohydrate crystal B-type material is as the health product dosage of active component:
Use the functional health that Arbidol hydrochloride monohydrate crystal B-type material manufactures as active component
Product, it is characterized in that in health product containing Arbidol hydrochloride monohydrate crystal B-type as healthcare active material, its consumption
From 5mg～50g.
List of references
1.Boriskin YS, Leneva IA, P é cheur EI, et al.Arbidol:a broad-spectrum
Antiviral compound that blocks viral fusion.Curr Med Chem.2008,15 (10): 997-
1005.
2.Shi L, Xiong H, He J, et al.Antiviral activity of arbidol against
Influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and
Adenovirus in vitro and in vivo.Arch Virol.2007,152 (8): 1447-1455.
3. a rubine, Sun Jingxia, Jiang Hong, etc. pharmacokinetics in human body of. Arbidol Hydrochloride Granules in Human Plasma and bioequivalence
Journal of Sex Research [J]. Chinese Pharmaceutical Journal, 2006,41 (23): 1814-1817.
4. discipline twilight, Zhao Yanhong, Zhang Min, etc. experiment in vitro research [J] of arbidol anti-SARS virus. liberation medical officer
Journal, 2004,20 (4): 274-276.
5. Chinese patent, publication number CN 1589790A
6. Chinese patent, publication number CN 1868470A
7. Chinese patent, publication number CN 101904826A
8. Chinese patent, publication number CN 101653425A
9. Chinese patent, publication number CN 1792362A
10. Chinese patent, publication number CN 1535680A
11. Chinese patents, publication number CN 1572298A
12. Chinese patents, publication number CN 1839829A
13. Chinese patents, publication number CN 1546019A
14. Chinese patents, publication number CN 1552321A
15. Chinese patents, publication number CN 101011389A
16. Chinese patents, publication number CN 1596892A
17. Chinese patents, publication number CN 101461805A
18. Journal of Chinese Hospital Pharmacies, 2006, volume 26, the 4th phase, page 397.
Claims (11)
1. the Arbidol hydrochloride monohydrate crystal B-type shown in formula (I),
It is characterized in that, when using CuK α radiation experiments condition when using powder x-ray diffraction analysis, show as Height%
=100 peak positions in 2-Theta=4.8 ± 0.2 ° orPlace also there are 30 its positions of diffraction maximum and divides
Not in 2-Theta (°) ± 0.2 ° value orValue has and is expressed as:
And diffraction maximum relative intensity value allows Height% ± 10% excursion.
2. a preparation method for Arbidol hydrochloride monohydrate crystal B-type sample as described in claim 1, its feature
It is, uses methanol solvate to be slowly added to phase after being completely dissolved by Arbidol hydrochloride sample under 65-80 DEG C of counterflow condition
The water of same volume reflux under the conditions of temperature 65-80 DEG C 3 hours after filtered while hot put crystallize by gentle and quiet for filtrate chamber, prepare
Arbidol hydrochloride monohydrate crystal B-type sample.
3. a preparation method for Arbidol hydrochloride monohydrate crystal B-type sample as described in claim 1, its feature
Be, add volume ratio be the methanol of 1:1 and water mixed solvent by Arbidol hydrochloride sample under 65-80 DEG C of temperature conditions
Filtered while hot put crystallize by gentle and quiet for filtrate chamber after refluxing 3 hours, prepares Arbidol hydrochloride monohydrate crystal B-type sample
Product.
4. a medicine, it is characterised in that become to be allocated as with the Arbidol hydrochloride monohydrate crystal B-type described in claim 1
For active component, and containing other adjuvants.
Medicine the most according to claim 4, it is characterised in that the crystal formation of described Arbidol hydrochloride monohydrate crystal B-type
Purity is 1%～100%.
Medicine the most according to claim 4, the dosage form of described medicine selected from tablet, capsule, pill, injection, slow release or controlled release agent,
Powder.
7. health product, it is characterised in that with the Arbidol hydrochloride monohydrate crystal B-type composition described in claim 1
As active component, and containing other adjuvants.
Health product the most according to claim 7, it is characterised in that the crystalline substance of described Arbidol hydrochloride monohydrate crystal B-type
Type purity is 1%～100%.
Health product the most according to claim 7, the dosage form of described health product is selected from tablet, capsule, pill, injection, slow release or control
Release agent, powder.
10. the Arbidol hydrochloride monohydrate crystal B-type of claim 1 application in preparation antiviral drugs.
11. application according to claim 10, described virus is selected from A, Type B influenza virus, SARS virus, hepatitis B
Poison, inhibition of HIV, Hantaan virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110128507.1A CN102786462B (en) | 2011-05-18 | 2011-05-18 | Arbidol hydrochloride crystal B-type and preparation method are applied with in medicine and health product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110128507.1A CN102786462B (en) | 2011-05-18 | 2011-05-18 | Arbidol hydrochloride crystal B-type and preparation method are applied with in medicine and health product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102786462A CN102786462A (en) | 2012-11-21 |
| CN102786462B true CN102786462B (en) | 2016-08-31 |
Family
ID=47152070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110128507.1A Active CN102786462B (en) | 2011-05-18 | 2011-05-18 | Arbidol hydrochloride crystal B-type and preparation method are applied with in medicine and health product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102786462B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106366029A (en) * | 2016-08-19 | 2017-02-01 | 江苏吴中医药集团有限公司苏州制药厂 | Arbidol mesylate monohydrate crystal C and its preparation method and use |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198552A (en) * | 1989-01-12 | 1993-03-30 | Trofimov Fedor A | Indole derivative having antiviral, interferon-inducing and immunomodulatory effects |
| RU2008004C1 (en) * | 1986-06-25 | 1994-02-28 | Центр по химии лекарственных средств - ВНИХФИ | Prophylactic and curative agent for treating flu virus b |
| CN1687033A (en) * | 2005-04-26 | 2005-10-26 | 武汉大学 | Medication for anti virus of respiratory tract and application |
| CN101084892A (en) * | 2005-04-26 | 2007-12-12 | 武汉大学 | Anti-respiratory virus medicine and use |
| CN101084893A (en) * | 2005-04-26 | 2007-12-12 | 武汉大学 | Anti-respiratory virus medicine and use |
| US20090326037A1 (en) * | 2005-12-28 | 2009-12-31 | Irina Anatolievna Leneva | Medicinal Agent For Treating Viral Infections |
| CN101653425A (en) * | 2009-09-15 | 2010-02-24 | 山东罗欣药业股份有限公司 | Arbidol hydrochloride medicament composition dispersible tablets and preparation method thereof |
-
2011
- 2011-05-18 CN CN201110128507.1A patent/CN102786462B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008004C1 (en) * | 1986-06-25 | 1994-02-28 | Центр по химии лекарственных средств - ВНИХФИ | Prophylactic and curative agent for treating flu virus b |
| US5198552A (en) * | 1989-01-12 | 1993-03-30 | Trofimov Fedor A | Indole derivative having antiviral, interferon-inducing and immunomodulatory effects |
| CN1687033A (en) * | 2005-04-26 | 2005-10-26 | 武汉大学 | Medication for anti virus of respiratory tract and application |
| CN101084892A (en) * | 2005-04-26 | 2007-12-12 | 武汉大学 | Anti-respiratory virus medicine and use |
| CN101084893A (en) * | 2005-04-26 | 2007-12-12 | 武汉大学 | Anti-respiratory virus medicine and use |
| US20090326037A1 (en) * | 2005-12-28 | 2009-12-31 | Irina Anatolievna Leneva | Medicinal Agent For Treating Viral Infections |
| CN101653425A (en) * | 2009-09-15 | 2010-02-24 | 山东罗欣药业股份有限公司 | Arbidol hydrochloride medicament composition dispersible tablets and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| Structural characterization of arbidol;Vladimir V. Chernyshev,等;《Zeitschrift fuer Kristallographie - Crystalline Materials》;20111231;第226卷(第11期);第832-836页 * |
| Synthesis of the new antiviral drug Arbidol;Trofimov F.A.,等;《Khim-Farm Zh》;19931231;第27卷(第1期);第70-71页 * |
| 抗流感病毒药阿比朵尔及其衍生物的合成研究;吴秀静;《沈阳药科大学硕士学位论文》;20040315;第32页 * |
| 盐酸阿比朵尔的合成;王钝,等;《中国医药工业杂志》;20040820;第35卷(第08期);第457-458页 * |
| 盐酸阿比朵尔的合成路线图解;温艳珍,等;《中国医药工业杂志》;20061210;第37卷(第12期);第862-864页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102786462A (en) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109996798B (en) | N- [5- (aminosulfonyl) -4-methyl-1, 3-thiazol-2-yl ] -N-methyl-2- [4- (2-pyridyl) -phenyl ] -acetamide free base hemihydrate, its preparation method and use | |
| CN101461949B (en) | Berberine cyclodextrin inclusion compound, preparation thereof and preparation method | |
| US20180044342A1 (en) | Crystal form of jak inhibitor and preparation method thereof | |
| CN103917536A (en) | 1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors | |
| NZ575786A (en) | Crystalline forms of thiazolidinedione derivative and its manufacturing method | |
| KR20120114174A (en) | 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid crystalline form and the producing method thereof | |
| CN105985394A (en) | Novel sofosbuvir crystal form and preparation method thereof | |
| WO2019011350A1 (en) | Fenlean (flz) crystal g form, preparation method, and composition and use thereof | |
| CN104016978B (en) | Palmatine hydrochloride crystal form C as well as preparation method thereof and application thereof in medicament composition or health-care product | |
| CN102786462B (en) | Arbidol hydrochloride crystal B-type and preparation method are applied with in medicine and health product | |
| CN102786519B (en) | Praziquantel crystal B substance, its preparation method and its applications in medicines and healthcare products | |
| CN102786573B (en) | Glycyrrhetinic acid crystal B-type material and preparation method and apply in medicine and healthcare products | |
| CN102786518B (en) | Palmatine hydrochloride crystal B-type material and preparation method are applied with in medicine and health product | |
| CN102786461B (en) | Arbidol hydrochloride crystalline substance E type and preparation method are applied with in medicine and health product | |
| CN114644642B (en) | Crystal form A of thienopyridine compound, preparation method and pharmaceutical composition thereof | |
| CN110302386A (en) | Combination product comprising limonoid and sulfonylureas | |
| CN103319436B (en) | The preparation of injection stage Vetamox (Am Cyanamid). and process for purification and lyophilized formulations thereof | |
| CN104817556A (en) | 9-O-ibuprofen berberine ester compound as well as preparation method and application of 9-O-ibuprofen berberine ester compound | |
| CN102786520A (en) | Praziquantel crystal A substance, its preparation method and its applications in medicines and healthcare products | |
| CN103864776B (en) | A kind of Tegafur derivative containing 1,3,4-thiadiazoles heterocycle and amide group | |
| CN109232297A (en) | Fragrant happy amine crystal B-type, preparation method and its composition and purposes | |
| CN107245054A (en) | A kind of amorphous bulleyaconitine A compound and preparation method thereof | |
| CN106632373A (en) | A D crystal form solid substance of bergenin, a preparing method thereof and uses of the substance | |
| CN107200719B (en) | A kind of crystalline substance VII type substance of 990207-22-1, its preparation method and its pharmaceutical composition and purposes | |
| CN102786521B (en) | Risperidone brilliant type III material and preparation method and apply in medicine and healthcare products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |